騰(teng)盛博(bo)藥已(yi)建立一條針(zhen)對傳染(ran)(ran)病(bing)(bing)(bing)及(ji)CNS疾病(bing)(bing)(bing)的(de)由10多(duo)個創新候(hou)選產品組(zu)成(cheng)的(de)管線(xian)，涵蓋臨床前到(dao)臨床階段項(xiang)目(mu)。亦有(you)權對授(shou)權合作(zuo)伙伴的(de)最(zui)多(duo)五個額外創新項(xiang)目(mu)進行授(shou)權新藥。公司現有(you)管線(xian)中的(de)候(hou)選藥物主要專注(zhu)于傳染(ran)(ran)病(bing)(bing)(bing)及(ji)CNS疾病(bing)(bing)(bing)。

招股(gu)(gu)(gu)(gu)(gu)(gu)書顯示，騰盛博(bo)藥在上市前的(de)股(gu)(gu)(gu)(gu)(gu)(gu)東架構中，Boyu Capital(博(bo)裕資本)，持(chi)有(you)(you)(you)18.53%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；6 Dimensions Capital，持(chi)有(you)(you)(you)17.80%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；ARCH，持(chi)有(you)(you)(you)17.80%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；紅(hong)杉，持(chi)有(you)(you)(you)9.72%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；Vir，持(chi)有(you)(you)(you)5.68%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；董事會主席兼首席執(zhi)行官 Zhi Hong持(chi)有(you)(you)(you)5.45%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；Invesco，持(chi)有(you)(you)(you)3.64%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；Blue Pool，持(chi)有(you)(you)(you)3.02%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；GIC，持(chi)有(you)(you)(you)2.18%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；SMALLCAP World Fund，持(chi)有(you)(you)(you)2.18%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；LBC，持(chi)有(you)(you)(you)0.73%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；高(gao)瓴資本，持(chi)有(you)(you)(you)0.36%的(de)股(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)；部分管理團隊成員、獨(du)立第三方等(deng)分別透過信(xin)托或其他方式合計持(chi)股(gu)(gu)(gu)(gu)(gu)(gu)2.37%。

招股書(shu)顯示，在過去的2019年和2020年兩個財政(zheng)年度，騰盛博藥未有營業收入，其(qi)相應(ying)(ying)期(qi)間的研發開(kai)支分(fen)別為人民幣0.84億(yi)和8.76億(yi)元人民幣，相應(ying)(ying)的凈虧損分(fen)別為5.35億(yi)和11.73億(yi)元人民幣。

>>